Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients with First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical Trial

S Chopra; SM Francey; B O'Donoghue; K Sabaroedin; A Arnatkeviciute; V Cropley; B Nelson; J Graham; L Baldwin; S Tahtalian; HP Yuen; K Allott; M Alvarez-Jimenez; S Harrigan; C Pantelis; SJ Wood; P McGorry; A Fornito

Journal article

Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients with First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical Trial

S Chopra, SM Francey, B O'Donoghue, K Sabaroedin, A Arnatkeviciute, V Cropley, B Nelson, J Graham, L Baldwin, S Tahtalian, HP Yuen, K Allott, M Alvarez-Jimenez, S Harrigan, C Pantelis, SJ Wood, P McGorry, A Fornito

JAMA Psychiatry | AMER MEDICAL ASSOC | Published : 2021

DOI: 10.1001/jamapsychiatry.2021.1422

Download PDF

Abstract

Importance: Altered functional connectivity (FC) is a common finding in resting-state functional magnetic resonance imaging (rs-fMRI) studies of people with psychosis, yet how FC disturbances evolve in the early stages of illness, and how antipsychotic treatment influences these disturbances, remains unknown. Objective: To investigate longitudinal FC changes in antipsychotic-naive and antipsychotic-treated patients with first-episode psychosis (FEP). Design, Setting, and Participants: This secondary analysis of a triple-blind, randomized clinical trial was conducted over a 5-year recruitment period between April 2008 and December 2016 with 59 antipsychotic-naive patients with FEP receiving e..

View full abstract

University of Melbourne Researchers

Sidhant Chopra Author

Shona Francey Author

Brian O'Donoghue Author

Vanessa Cropley Author

Related Projects (4)

NEUROBIOLOGICAL 'RISK' AND 'RESILIENCE' BIOMARKERS OF SEVERE MENTAL ILLNESS

Mental disorders of childhood (schizotypal disorder, autism spectrum disorders) and adolescence (psychoses, schizophrenia) represent a major..

CAN WE PREDICT PSYCHOSIS AND CAN IT BE PREVENTED?

It remains unclear what the causes of schizophrenia and other psychotic disorders are and what the most effective interventions are for prev..

NEUROINFLAMMATION IN SCHIZOPHRENIA

This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using no..

ANTIPSYCHOTIC MEDICATION IN FIRST-EPISODE PSYCHOSIS: AN RCT TO ASSESS THE RISK-BENEFIT RATIO

There has been an increasing emphasis on intervening early in psychotic disorders. A fundamental principle in early intervention is “to do n..

Grants

Awarded by H. Lundbeck A/S

Funding Acknowledgements

This study was supported in part by grants 1105825 and 1196508 from the NHMRC Senior Principal Research Fellowship and the NHMRC L3 Investigator Grant, respectively (Prof Pantelis), and grant 1137687 from the NHMRC Senior Research Fellowship (Prof Nelson). Janssen-Cilag partially supported the early years of this study with an unrestricted investigator-initiated grant and provided risperidone, paliperidone, and matched placebo for the first 30 participants. The study was then funded by grant 1064704 from the Australian NHMRC Project (Dr Francey, Prof Nelson, Dr Allott, Dr Alvarez-Jimenez, Dr Harrigan, Prof McGorry, and Dr Fornito). Control participants were funded by NHMRC project grant 1065742 (Dr Cropley and Prof Pantelis). Dr Cropley was supported by NHMRC EL2 Investigator Grant 1177370.